{"id":"NCT02268045","sponsor":"mAbxience Research S.L.","briefTitle":"Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma","officialTitle":"A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2016-05","completion":"2017-07","firstPosted":"2014-10-20","resultsPosted":"2019-09-26","lastUpdate":"2019-09-26"},"enrollment":272,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diffuse Large B-cell Lymphoma"],"interventions":[{"type":"BIOLOGICAL","name":"RTXM83","otherNames":["Rituximab Biosimilar"]},{"type":"BIOLOGICAL","name":"Mabthera","otherNames":["Reference rituximab"]}],"arms":[{"label":"RTXM83","type":"EXPERIMENTAL"},{"label":"MabThera","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, double-blind, randomized study comparing the efficacy, pharmacokinetics (PK)/pharmacodynamics (PD), safety and immunogenicity profile of RTXM83 (rituximab biosimilar) vs reference rituximab (MabThera®), both with CHOP, as first-line treatment of Diffuse-Large-B-Cell-Lymphoma (DLBCL).\n\nRituximab biosimilar and MabThera® were both administered intravenously on Day 1 of each 3-week cycle with CHOP chemotherapy for six cycles. Two additional cycles of treatment were permitted at the Investigator's discretion. Patients were followed up for 9 months after last study dose.","primaryOutcome":{"measure":"Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL","timeFrame":"Tumor response assessed after Cycle 6 or at the end of treatment","effectByArm":[{"arm":"RTXM83-CHOP","deltaMin":83.6,"sd":null},{"arm":"MabThera-CHOP","deltaMin":82.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":87,"countries":["Argentina","Brazil","Colombia","India","Indonesia","Iran","Malaysia","Mexico","Paraguay","Philippines","Russia","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":136},"commonTop":["Neutropenia","Anaemia","Nausea","Leukopenia","Alopecia"]}}